REG - OptiBiotix Health - First German sales <Origin Href="QuoteRef">OPTIO.L</Origin>

OptiBiotix HealthAnnouncement

25/04/2017 08:55

RNS Number : 2319D
OptiBiotix Health PLC
25 April 2017
OptiBiotix Health plc
("OptiBiotix" or the "Company")
First sales ofLPLDL to German market
OptiBiotixHealthplc(AIM:OPTI),alifesciencesbusinessdevelopingcompoundstotackleobesity,high cholesterol,diabetes and skin care,announces that it has agreed to supply 100,000 units of LPLDL to HLH BioPharma Vertriebs GmbH ("HLH").
HLH have over 20 years' experience in the distribution of probiotic and natural products under the brand names Lactobact and Casa Sana and is one of Europe's leading suppliers of probiotics to the pharmacy market.
HLH is based in Germany and has established an international reputation for providing high quality and scientifically validated innovative products. LPLDL will be supplied as bulk capsules which will be packaged and branded as part of HLH's market leading Lactobact brand.
This pre-launch sale provides moderate levels of early income and reflects the high level of industry awareness in LPLDL as a functional component in a wide range of consumer healthcare and pharmaceutical products. This interest arises from OptiBiotix's innovative science, good clinical data, strong key opinion leader support, and the products ability to reduce both cholesterol and blood pressure. The European Society of Cardiology Studies has reported the ability to reduce both cholesterol and blood pressure 'has a multiplicative effect in reducing cardiovascular risk' providing a significant advantage over single action products.
This sales order is the first step in a business to business (B2B) strategy of bringing OptiBiotix's science together with a partner's national brand portfolio and market presence to serve multiple consumer healthcare and pharmaceutical markets around the world.
Stephen O'Hara, CEO of OptiBiotix, commented: "We are pleased to announce the supply of LPLDL to HLH which will be sold as part of its market leadingLactobact brand.We see this as the first step in building sales and market presence of LPLDL as the 'Intel' inside a wide range of products for cardiovascular health across both consumer and pharmaceutical markets around the world. This creates the opportunity for multiple revenue streams from sales of the strain, white label, and branded products in different presentations and formulations to meet the needs of a diverse range of national and international markets."
OptiBiotix Health plc
www.optibiotix.com
Stephen O'Hara, Chief Executive
Contact via Walbrook below


Cairn Financial Advisers LLP (NOMAD)
Tel: 020 7213 0880
Liam Murray / Jo Turner

finnCap (Broker)
Tel: 020 7220 0500
Adrian Hargrave / Scott Mathieson / Kate Bannatyne (Corporate Finance)

Tony Quirke (Corporate Broking)



Walbrook PR Ltd
Tel: 020 7933 8780 or optibiotix@walbrookpr.com
Anna Dunphy
  Mob: 07876 741 001
About OptiBiotix - www.optibiotix.com
OptiBiotix was formed in March 2012 to develop compounds which modify the human microbiome - the collective genome of the microbes in the body - to prevent and manage human disease.
The aim of OptiBiotix is to discover and develop microbial strains, compounds and formulations, which modulate the human microbiome and can be used as food ingredients and supplements or active compounds for the prevention and management of human metabolic diseases, examples of which include obesity, cholesterol and lipid distribution and diabetes.
OptiBiotix has established a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest and appetite suppression. The development pipeline is fuelled by its proprietary OptiScreen and OptiBiotic platform technologies designed to identify metabolic pathways and compounds that impact on human physiology and bring potential health benefits. These platforms are applicable across a wider range of other human diseases. 

This information is provided by RNS
The company news service from the London Stock Exchange
  END
MSCDELBLDZFZBBK